These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 23719349)

  • 21. Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?
    Girard PM; Nelson M; Mohammed P; Hill A; van Delft Y; Moecklinghoff C
    AIDS; 2013 Nov; 27(17):2759-63. PubMed ID: 23842127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment.
    Zhang S; van Sighem A; Gras L; Reiss P; Smit C; Kroon F; Jurriaans S; Prins J; Lange J; de Wolf F
    Antivir Ther; 2010; 15(4):555-62. PubMed ID: 20587848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
    Lampe FC; Gatell JM; Staszewski S; Johnson MA; Pradier C; Gill MJ; de Lazzari E; Dauer B; Youle M; Fontas E; Krentz HB; Phillips AN
    Arch Intern Med; 2006 Mar; 166(5):521-8. PubMed ID: 16534038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women.
    Konopnicki D; Manigart Y; Gilles C; Barlow P; de Marchin J; Feoli F; Larsimont D; Delforge M; De Wit S; Clumeck N
    J Infect Dis; 2013 Jun; 207(11):1723-9. PubMed ID: 23463709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
    Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
    Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy.
    Guzmán-Fulgencio M; Berenguer J; Micheloud D; Fernández-Rodríguez A; García-Álvarez M; Jiménez-Sousa MA; Bellón JM; Campos Y; Cosín J; Aldámiz-Echevarría T; Catalán P; López JC; Resino S
    J Antimicrob Chemother; 2013 Oct; 68(10):2349-57. PubMed ID: 23749950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort.
    van Lelyveld SF; Gras L; Kesselring A; Zhang S; De Wolf F; Wensing AM; Hoepelman AI;
    AIDS; 2012 Feb; 26(4):465-74. PubMed ID: 22112603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy.
    Chaix ML; Seng R; Frange P; Tran L; Avettand-Fenoël V; Ghosn J; Reynes J; Yazdanpanah Y; Raffi F; Goujard C; Rouzioux C; Meyer L;
    Clin Infect Dis; 2013 Mar; 56(6):880-7. PubMed ID: 23223603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.
    Trotta MP; Cozzi-Lepri A; Ammassari A; Vecchiet J; Cassola G; Caramello P; Vullo V; Soscia F; Chiodera A; Ladisa N; Abeli C; Cauda R; Buonuomi AR; Antinori A; d'Arminio Monforte A;
    Clin Infect Dis; 2010 Aug; 51(4):456-64. PubMed ID: 20597690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short communication: effects of age on virologic suppression and CD4 cell response in HIV-positive patients initiating combination antiretroviral therapy.
    Szadkowski L; Tseng A; Walmsley SL; Salit I; Raboud JM
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1579-83. PubMed ID: 22734840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
    Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
    AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
    Mocroft A; Phillips AN; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren JD;
    Lancet; 2007 Aug; 370(9585):407-13. PubMed ID: 17659333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
    Moh R; Danel C; Messou E; Ouassa T; Gabillard D; Anzian A; Abo Y; Salamon R; Bissagnene E; Seyler C; Eholié S; Anglaret X
    AIDS; 2007 Nov; 21(18):2483-91. PubMed ID: 18025885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.